» Articles » PMID: 38664329

Implications of Cardiopulmonary Risk for the Management of COPD: A Narrative Review

Overview
Journal Adv Ther
Date 2024 Apr 25
PMID 38664329
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic obstructive pulmonary disease (COPD) constitutes a major global health burden and is the third leading cause of death worldwide. A high proportion of patients with COPD have cardiovascular disease, but there is also evidence that COPD is a risk factor for adverse outcomes in cardiovascular disease. Patients with COPD frequently die of respiratory and cardiovascular causes, yet the identification and management of cardiopulmonary risk remain suboptimal owing to limited awareness and clinical intervention. Acute exacerbations punctuate the progression of COPD in many patients, reducing lung function and increasing the risk of subsequent exacerbations and cardiovascular events that may lead to early death. This narrative review defines and summarises the principles of COPD-associated cardiopulmonary risk, and examines respiratory interventions currently available to modify this risk, as well as providing expert opinion on future approaches to addressing cardiopulmonary risk.

Citing Articles

Improving COPD Management at Transitions of Care.

Kaplan A Fed Pract. 2025; 41(Suppl 6):S29-S34.

PMID: 39839062 PMC: 11745471. DOI: 10.12788/fp.0533.


Sex-specific association of total mineral intake with pulmonary function in middle-aged and older adults with chronic obstructive pulmonary disease.

Zhang H, Tian W, Qi G, Wei X Sci Rep. 2024; 14(1):29228.

PMID: 39587155 PMC: 11589574. DOI: 10.1038/s41598-024-79862-6.


COPD is associated with increased cardiovascular disease risk independent of phenotype.

Cobb K, Kenyon J, Lu J, Krieger B, Perelas A, Nana-Sinkam P Respirology. 2024; 29(12):1047-1057.

PMID: 39019777 PMC: 11570344. DOI: 10.1111/resp.14799.

References
1.
. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med. 1980; 93(3):391-8. DOI: 10.7326/0003-4819-93-3-391. View

2.
Williams M, Murchison J, Edwards L, Agusti A, Bakke P, Calverley P . Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax. 2014; 69(8):718-23. DOI: 10.1136/thoraxjnl-2012-203151. View

3.
Pullen R, Miravitlles M, Sharma A, Singh D, Martinez F, Hurst J . CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care. Int J Chron Obstruct Pulmon Dis. 2021; 16:2301-2322. PMC: 8370848. DOI: 10.2147/COPD.S313498. View

4.
Amegadzie J, Sadatsafavi M . A long overdue recognition: COPD as a distinct predictor of cardiovascular disease risk. Eur Respir J. 2023; 62(2). DOI: 10.1183/13993003.01167-2023. View

5.
Chen W, Thomas J, Sadatsafavi M, FitzGerald J . Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015; 3(8):631-9. DOI: 10.1016/S2213-2600(15)00241-6. View